Massachusetts, USA-based DMS Data Systems has announced the launch of Clinical Trials Plus, an on-line searchable database of clinical trials designed for business and clinical development, competitive intelligence and investment professionals in the pharmaceutical, biotechnology, medical device and diagnostics industries.
The new database (www.clinicaltrialsplus.com) contains all studies registered with clinicaltrials.gov, the largest clinical trials registry in the world, with over 30,000 individual evaluations. The database has powerful search features, the ability to set up e-mail alerts tracking new trials on any subject, and the ability to create PDF documents from the results of searches, says DMS, adding that it is updated daily, and has links to related industry news and company profiles.
The growth in the number of registered studies has been striking since the International Committee of Medical Journal Editors announced that it would require a trial to be registered if its results were ultimately to be published. There were over 11,000 trials registered in 2005 and there have been over 7,000 so far this year. "Managing this volume of new information, and extracting its value, is a formidable task, which can now be accomplished very easily with our new database," said Rick Franklin, chairman of the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze